ABIVAX Société Anonyme (AAVXF PINK) stock market data APIs
$118.3477
0(0%)
as of December 24, 2025
Try our APIs with
free plan!
ABIVAX Société Anonyme Financial Data Overview
Price chart is built with
Anychart
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Prev. Close
118.3477
Open
118.3477
High
118.3477
Low
118.3477
52 wk Range
5.81-133.4
Market Cap
9 262 M
Shares Outstanding
77 931 K
Revenue
5 311 K
EPS
-2.4568
Beta
-0.112
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ABIVAX Société Anonyme (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ABIVAX Société Anonyme data using free add-ons & libraries
Get ABIVAX Société Anonyme Fundamental Data
ABIVAX Société Anonyme Fundamental data includes:
- Net Revenue: 5 311 K
- EBITDA: -217 952 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ABIVAX Société Anonyme News
New
Abivax soars on report of Eli Lilly meeting French officials over possible deal
Investing.com -- Abivax shares jumped after fresh media reports revived speculation that U.S. drugmaker Eli Lilly is exploring a takeover of the French biotech company. The stock was up 9% in Paris b...
Abivax to be Added to Nasdaq Biotechnology Index
Abivax Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the...
Barclays Initiates ABIVAX Société (ABVX) With Overweight Rating
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the Hot Growth Stocks to Invest in Now. On October 13, Etzer Darout from Barclays initiated ABIVAX Société Anonyme (NASDAQ:ABVX) with an Overweigh...
Citizens JMP Raises PT on ABIVAX Société Anonyme (ABVX) Stock
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 25, Citizens JMP lifted the price target on the company’s stock to $114 fr...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
